On Visit To Japan, Sanofi’s Viehbacher Weighs In On Innovation Models, Clinical Trial Transparency
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased funding and public-private interaction in a new research “control tower” would be welcomed by industry in Japan, Viehbacher said. But the CEO opposes expanded regulatory oversight on clinical trial transparency.
You may also be interested in...
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.